These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

175 related articles for article (PubMed ID: 34411990)

  • 21. The pro-inflammatory cytokine, interleukin-6, enhances the polarization of alternatively activated macrophages.
    Fernando MR; Reyes JL; Iannuzzi J; Leung G; McKay DM
    PLoS One; 2014; 9(4):e94188. PubMed ID: 24736635
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Targeting Interleukin-6 Signaling in Clinic.
    Kang S; Tanaka T; Narazaki M; Kishimoto T
    Immunity; 2019 Apr; 50(4):1007-1023. PubMed ID: 30995492
    [TBL] [Abstract][Full Text] [Related]  

  • 23. IL-6 transsignaling: the in vivo consequences.
    Jones SA; Richards PJ; Scheller J; Rose-John S
    J Interferon Cytokine Res; 2005 May; 25(5):241-53. PubMed ID: 15871661
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Pro- versus anti-inflammatory cytokines: myth or reality.
    Cavaillon JM
    Cell Mol Biol (Noisy-le-grand); 2001 Jun; 47(4):695-702. PubMed ID: 11502077
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Effects of blockade of peripheral interleukin-6 trans-signaling on hippocampus-dependent and independent memory in mice.
    Braun O; Dewitz C; Möller-Hackbarth K; Scheller J; Schiffelholz T; Baier PC; Rose-John S
    J Interferon Cytokine Res; 2013 May; 33(5):254-60. PubMed ID: 23215755
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Blockade of IL-6 signal exacerbates acute inflammatory bowel disease via inhibiting IL-17 producing in activated CD4+ Th17 population.
    Zhang SJ; Wang L; Ming L; Guo XB; Wang HM; Li XW; Li L
    Eur Rev Med Pharmacol Sci; 2013 Dec; 17(24):3291-5. PubMed ID: 24379058
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Cytokines are a therapeutic target for the prevention of inflammation-induced cancers.
    Rose-John S; Schooltink H
    Recent Results Cancer Res; 2007; 174():57-66. PubMed ID: 17302185
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Anti-Inflammatory Effect of Muscle-Derived Interleukin-6 and Its Involvement in Lipid Metabolism.
    Nara H; Watanabe R
    Int J Mol Sci; 2021 Sep; 22(18):. PubMed ID: 34576053
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Plasticity and cross-talk of interleukin 6-type cytokines.
    Garbers C; Hermanns HM; Schaper F; Müller-Newen G; Grötzinger J; Rose-John S; Scheller J
    Cytokine Growth Factor Rev; 2012 Jun; 23(3):85-97. PubMed ID: 22595692
    [TBL] [Abstract][Full Text] [Related]  

  • 30. IL-6 in diabetes and cardiovascular complications.
    Qu D; Liu J; Lau CW; Huang Y
    Br J Pharmacol; 2014 Aug; 171(15):3595-603. PubMed ID: 24697653
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Coronavirus-19 (SARS-CoV-2) induces acute severe lung inflammation via IL-1 causing cytokine storm in COVID-19: a promising inhibitory strategy.
    Conti P; Caraffa A; Gallenga CE; Ross R; Kritas SK; Frydas I; Younes A; Ronconi G
    J Biol Regul Homeost Agents; 2020; 34(6):1971-1975. PubMed ID: 33016027
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Generation of Soluble Interleukin-11 and Interleukin-6 Receptors: A Crucial Function for Proteases during Inflammation.
    Lokau J; Agthe M; Garbers C
    Mediators Inflamm; 2016; 2016():1785021. PubMed ID: 27493449
    [TBL] [Abstract][Full Text] [Related]  

  • 33. The biology of interleukin-27 reveals unique pro- and anti-inflammatory functions in immunity.
    Aparicio-Siegmund S; Garbers C
    Cytokine Growth Factor Rev; 2015 Oct; 26(5):579-86. PubMed ID: 26195434
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Interleukin-6 and its receptors: a highly regulated and dynamic system.
    Wolf J; Rose-John S; Garbers C
    Cytokine; 2014 Nov; 70(1):11-20. PubMed ID: 24986424
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Targeting interleukin-6 in inflammatory autoimmune diseases and cancers.
    Yao X; Huang J; Zhong H; Shen N; Faggioni R; Fung M; Yao Y
    Pharmacol Ther; 2014 Feb; 141(2):125-39. PubMed ID: 24076269
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Inhibitory effects of suppressor of cytokine signaling 3 on inflammatory cytokine expression and migration and proliferation of IL-6/IFN-γ-induced vascular smooth muscle cells.
    Xiang S; Dong NG; Liu JP; Wang Y; Shi JW; Wei ZJ; Hu XJ; Gong L
    J Huazhong Univ Sci Technolog Med Sci; 2013 Oct; 33(5):615-622. PubMed ID: 24142708
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Cardiovascular biology of interleukin-6.
    Abeywardena MY; Leifert WR; Warnes KE; Varghese JN; Head RJ
    Curr Pharm Des; 2009; 15(15):1809-21. PubMed ID: 19442192
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Signal transduction through gp130 that is shared among the receptors for the interleukin 6 related cytokine subfamily.
    Hirano T; Matsuda T; Nakajima K
    Stem Cells; 1994 May; 12(3):262-77. PubMed ID: 8075593
    [TBL] [Abstract][Full Text] [Related]  

  • 39. The role of IL-6 in host defence against infections: immunobiology and clinical implications.
    Rose-John S; Winthrop K; Calabrese L
    Nat Rev Rheumatol; 2017 Jul; 13(7):399-409. PubMed ID: 28615731
    [TBL] [Abstract][Full Text] [Related]  

  • 40. The pro- and anti-inflammatory properties of the cytokine interleukin-6.
    Scheller J; Chalaris A; Schmidt-Arras D; Rose-John S
    Biochim Biophys Acta; 2011 May; 1813(5):878-88. PubMed ID: 21296109
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 9.